KYTX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Sep 24, 2026

8-K

Kyverna Therapeutics Reports Q2 2026 Financial Results and Pipeline Progress

Aug 11, 2026

8-K

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

Jul 27, 2026

8-K

Kyverna Therapeutics Amends Loan and Security Agreement to Extend Term A Loan Availability

Jul 9, 2026

8-K

Kyverna Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 2, 2026

8-K

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

May 18, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* April 2026 ATM | Offering amount: $100,000,000 | Bank: Jefferies LLC

Apr 2, 2026

424B5

REGISTERED OFFERING

Dec 17, 2025

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $100,000,000 | Bank: J.P. Morgan, Leerink Partners, Morgan Stanley, Wells Fargo Securities

Dec 15, 2025

424B5

April ATM | Offering amount: $50,000,000

Apr 15, 2025

424B4

OFFERING | Shares amount: 14,500,000 | Share price: $22.00 | Offering amount: $319,000,000.00

Feb 8, 2024

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 13, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 13, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 14, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 14, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

HIRSCHMAN ORIN (Filed by)

Oct 19, 2026

SCHEDULE 13G/A

Bain Capital Life Sciences Opportunities III, LP (Filed by)

Aug 14, 2026

SCHEDULE 13G

BlackRock, Inc. (Filed by)

Jul 29, 2026

CLARK IAN T (Reporting)

May 29, 2026

Cohen Fred E (Reporting)

May 29, 2026

SEIDENBERG BETH C (Reporting)

May 29, 2026

Other

TYPE

HEADLINE

FILED AT

Kyverna Therapeutics, Inc. KYTX · SEC Filings